Lymphodepletion with high-dose interleukin-2 (IL-2) and granulocyte macrophage-colony stimulating factor (GM-CSF) in metastatic melanoma patients: An interim analysis.

被引：0

作者：

Ketchum, S. L.

Cole, B.

Margolin, K.

McDermott, D.

Crocenzi, T.

Roberts, J.

Crosby, N.

Meehan, K.

Fisher, J.

Ernstoff, M. S.

机构：

[1] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[2] Harvard Univ, Cambridge, MA 02138 USA

[3] Virginia Commonwealth Univ, Richmond, VA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8034

引用

页码：461S / 461S

页数：1

共 50 条

[1] Phase II Study of thalidomide, Interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC).
Rawat, A
Arnato, RJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 431S - 431S
[2] Phase II study of thalidomide, interleukin-2 (IL-2) plus granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (MRCC).
Amato, R
Rawat, A
Attumi, T
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8977S - 8977S
[3] Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma
Chu, Melinda Bernabe
Fesler, Mark
Armbrecht, Eric
Fosko, Scott
Hsueh, Eddy C.
Richart, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[4] In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma
Hasskamp, Joanne H.
Elias, E. George
Zapas, John L.
JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (04) : 331 - 338
[5] In Vivo Effects of Sequential Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-2 (IL-2) on Circulating Dendritic Cells (DC) in Patients with Surgically Resected High Risk Cutaneous Melanoma
JOANNE H. HASSKAMP
E. GEORGE ELIAS
JOHN L. ZAPAS
Journal of Clinical Immunology, 2006, 26 : 331 - 338
[6] GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) INCREASES IL-2 BINDING ON HUMAN NEUTROPHILS
GIRARD, D
HEITZ, D
GOSSELIN, J
BEAULIEU, A
CLINICAL RESEARCH, 1994, 42 (03): : A460 - A460
[7] Phase Ii study of low-dose outpatient chemobiotherapy with temozolomide (TMZ), granulocyte macrophage colony stimulating factor (GM-CSF), Interferon-alpha-2b (IFN), and Interleukin-2 (IL-2) for the treatment of metastatic melanoma.
Weber, RW
O'Day, S
Rose, M
Ames, P
Good, J
Meyer, J
Allen, R
Trautvetter, S
Timmerman, M
Gonzalez, R
Spitler, LE
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 721S - 721S
[8] Interleukin-2 (IL-2) and granulocyte-macrophage stimulating factor (GM-CSF) for treatment of relapse after allogeneic stem cell transplant (ASCT)
Bachier, CR
Shaughnessy, P
Wall, D
Grimley, M
LeMaistre, CF
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 56 - 56
[9] Phase H trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.
Lutzky, J.
Lawson, D. H.
Enriquez-Nunez, Y.
Gabrilovich, D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[10] Granulocyte-macrophage colony stimulating factor (GM-CSF) & interleukin-2 (IL-2) combination as adjuvant therapy in cutaneous melanoma. Early results of a phase II clinical trial.
Elias, EG
Zapas, JL
Beam, SL
Brown, SD
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 724S - 724S

← 1 2 3 4 5 →